04:06 PM EDT, 05/12/2025 (MT Newswires) -- AbCellera Biologics ( ABCL ) said Monday that the US Court of Appeals for the Federal Circuit has affirmed judgment of validity of its US patent 10,087,408, which is directed to microfluidic devices used for culturing and selectively recovering cells.

The patent was challenged by Bruker Cellular Analysis, a subsidiary of Bruker ( BRKR ) , which alleged invalidity based on "anticipation and obviousness over the prior art," the company said. However, Bruker's ( BRKR ) arguments were rejected by the US Patent Trial and Appeal Board.

AbCellera's patent is part of a multi-patent infringement litigation between AbCellera and Bruker ( BRKR ) pending in the US District Court for the Northern District of California.

Bruker ( BRKR ) didn't immediately respond to a request for comment from MT Newswires.

Price: 2.07, Change: +0.04, Percent Change: +1.72